Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier by Grabacka, M. et al.
INTRODUCTION
Invasiveness and metastatic dissemination characterize
neuroectodermal tumors such as glioblastoma, neuroblastoma,
medulloblastoma and melanoma. Despite the growing
knowledge about their etiology and efforts to develop improved
tools for early diagnosis and treatment, their invasive phenotype
results in high mortality rates, especially among children and
young adults. Brain tumors are particularly difficult to treat due
to distinct anatomical and physiological traits of neural tissue
and vasculature. The blood brain barrier (BBB) and blood-brain
tumor barrier (BTB) represent the major obstacles that prevent
chemotherapeutic agents from reaching intracranial tumors.
Several strategies have been developed to enhance BBB and
BTB permeability via biochemical intervention. Carotid artery
infusion with hyperosmotic (1.6 M) mannitol was shown to
temporarily open BBB, by induction of endothelial cells
shrinkage and tight junction disruption. However, the opening
lasts less than 30 minutes, leaving a very narrow window for
potential drug delivery (1, 2). Another strategy for more
selective BTB opening involves the use of vasomodulators, most
commonly bradykinin or nitric oxide donors, which are able to
transiently (for 15–120 minutes) increase capillary permeability
(3, 4). However, the use of bradykinin promotes glioma cell
migration, invasion and tumor angiogenesis and this drug acts as
a chemoattractant that guides glioma cells to the blood vessels
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Fenofibrate, a well-known normolipidemic drug, has been shown to exert strong anticancer effects against tumors of
neuroectodermal origin including glioblastoma. Although some pharmacokinetic studies were performed in the past,
data are still needed about the detailed subcellular and tissue distribution of fenofibrate (FF) and its active metabolite,
fenofibric acid (FA), especially in respect to the treatment of intracranial tumors. We used high performance liquid
chromatography (HPLC) to elucidate the intracellular, tissue and body fluid distribution of FF and FA after oral
administration of the drug to mice bearing intracranial glioblastoma. Following the treatment, FF was quickly cleaved
to FA by blood esterases and FA was detected in the blood, urine, liver, kidney, spleen and lungs. We have also detected
small amounts of FA in the brains of two out of six mice, but not in the brain tumor tissue. The lack of FF and FA in the
intracranial tumors prompted us to develop a new method for intracranial delivery of FF. We have prepared and tested
in vitro biodegradable poly-lactic-co-glycolic acid (PLGA) polymer wafers containing FF, which could ultimately be
inserted into the brain cavity following resection of the brain tumor. HPLC-based analysis demonstrated a slow and
constant diffusion of FF from the wafer, and the released FF abolished clonogenic growth of glioblastoma cells. On the
intracellular level, FF and FA were both present in the cytosolic fraction. Surprisingly, we also detected FF, but not FA
in the cell membrane fraction. Electron paramagnetic resonance spectroscopy applied to spin-labeled phospholipid
model-membranes revealed broadening of lipid phase transitions and decrease of membrane polarity induced by
fenofibrate. Our results indicate that the membrane-bound FF could contribute to its exceptional anticancer potential in
comparison to other lipid-lowering drugs, and advocate for intracranial delivery of FF in the combined pharmacotherapy
against glioblastoma.
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(5, 6), thus increasing the aggressiveness of the tumor. An
alternative effective way to overcome BBB and simultaneously
reduce systemic toxicity exerted by chemotherapeutic drugs was
reported by Henry Brem and his team in 1993, in a proof-of-
concept paper describing interstitial chemotherapy through bis-
chloroethylnitrosourea (BCNU) intracranial delivery in
biodegradable or nonbiodegradable wafers. The BCNU wafers
were tested in rats bearing 9L gliosarcoma intracranial tumors
and the treated animals survived significantly longer than the
control animals (receiving a placebo wafer) or those that
received intraperitoneal BCNU (7). This concept of a direct
delivery of chemotherapeutic agent to a tumor bed served as a
basis for development of Gliadel® wafers, which have been used
against recurrent glioblastoma tumors since 1996 (8).
Despite the moderate increase in the mean survival of
glioblastoma patients with implanted BCNU wafers, Gliadel®
has not fully fulfilled the hopes for effective treatment (8, 9). A
recent report on randomized control trials performed so far,
“demonstrated a significant survival benefit for Gliadel® only
after adjustment for prognostic factors and the prospective
cohort study reported no survival benefit for Gliadel® as
compared with a historical control group” (9). A number of
unanswered questions still remain about how to improve current
treatments or develop new, more effective multi-drug targeted
regimens against glial tumors. Progress in basic research
provides the frames for the development of new therapeutic
directions that employ modulation of tumor-associated
inflammatory responses, autophagy and application of bioactive
phytochemicals (10-12).
We present herein results that support a new approach to
glioblastoma treatment with fenofibrate (FF), a widely used
hypolipidemic drug with an exceptional anticancer potential.
The main advantages of using FF as a supportive
oncotherapeutic agent include its recently revealed broad
anticancer activities, low systemic toxicity, and good tolerance
even in chronic administration. Our recent studies have
demonstrated that FF effectively induces: 1) cell cycle arrest, 2)
blockage of migration and invasiveness, and 3) apoptotic death
in various tumor cells of neuroectodermal origin (13-17). In
spite of these very promising results, we still do not understand
how FF is so effective in targeting tumor cells while providing
low systemic toxicity (18).
Fenofibrate was launched for hypercholesterolemia
treatment in 1974 but its mechanism of action remained
unknown until the discovery of a novel member of the steroid
hormone receptor superfamily, called peroxisome proliferator
activated receptor alpha (PPARα) by Issemann and Green (19).
This report was preceded by studies demonstrating that fibrates
had a strong impact on the genes responsible for fatty acid
oxidation and lipoprotein metabolism (20, 21). Fenofibrate, or
more accurately its active metabolite, fenofibric acid (FA),
(Fig. 1) acts as an agonist of transcription factor PPARα.
PPARα transactivates a broad variety of genes involved in lipid
and glucose metabolism (22-24). Other drugs that share the
common structural aromatic motif with FF, such as gemfibrozil
or prinixic acid (Wy-14,643) (Fig. 1), are known to be potent
PPARα agonists (25). However, in contrast to FF, these latter
two compounds are not processed by cellular enzymes and
activate PPARα directly.
Interestingly, at least some effects of FF that contribute to its
anticancer activities seem to be PPARα independent. These
effects include inhibition of mitochondrial respiration and
alterations in plasma membrane fluidity (26-28). Importantly, FF
has been included in new anti-angiogenic therapeutic regimens
of combined chemotherapy with etoposide, cyclophosphamide,
thalidomide and celecoxib against progressive and relapsed
cancer that aim to reduce tumor neovascularization (29-31).
In this report we show HPLC-based analyses of FF
pharmacokinetics in cell culture and in various organs and body
fluids from animals after oral delivery. Because oral
administration did not provide the access of FF or FA to brain
tumor tissue, we also present a method for potential intracranial
delivery in which FF is incorporated in a wafer made of the poly-
lactate-co-glycolate (PLGA) that can be placed directly in the
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Fig. 1. Chemical structures of
fenofibrate (FF), fenofibric acid (FA),
gemfibrozil and Wy-14,643 (pirinixic
acid).
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cavity after the brain tumor resection in a similar fashion to
Gliadel® (7). Additionally, we demonstrate that FF but not FA is
present in the membrane fraction isolated from the glioblastoma
cells exposed to this lipid-lowering drug. Using electron
paramagnetic resonance (EPR) and spin-labeled liposomes, we
further show that the membrane-bound FF significantly alters
lipid phase transitions and decreases membrane polarity. This
unique property of FF could contribute to its exceptional
anticancer potential in comparison to other PPARα agonists or to
metformin, which all have been previously reported to have
putative anticancer potential (32).
MATERIALS AND METHODS
Cell culture
Human glioblastoma cell line LN-229 (ATCC# CRL-2611)
monolayer cultures were maintained in DMEM supplemented
with 50 U/ml penicillin, 50 ng/ml streptomycin, and 10% fetal
bovine serum (FBS) at 37°C and 5% CO2 atmosphere. For
HPLC analyses, the cells were seeded in 100 mm cell culture
dishes and cultured in the presence of 10% FBS supplemented
with FF (Sigma Aldrich, USA, at final concentration of 50 µM
diluted from DMSO stock). The medium and cellular samples
were collected after 6, 10, 24, 48 and 72 hours of incubation.
Membrane and cytosolic fractions were prepared from the
control (DMSO) and FF treated LN-229 cultures were prepared
using Membrane Fractionation kit (Abcam, UK), according to
the manufacturer’s protocol. Briefly, cells (1,000,000) were
trypsinized and centrifuged. The pellet was resuspended in 150
µl of Buffer A and subjected to further steps as described in the
protocol. The final membrane fraction (0.3 mL) was collected as
a supernatant after centrifugation, then an aliquot of 100 µl was
subjected to HPLC analysis (described below).
Animal studies
Foxn1 nude mice (6 week old females, average body weight
25 g) were purchased from Harlan Laboratories (Houston TX,
USA). The mice were maintained in groups of 5 animals/cages in
a pathogen-free environment, with 12 hours light/dark cycles and
free access to water and standard chow. Animals bearing
intracranial human glioblastoma (LN-229) were given micronized
FF (Lipanthyl 200M, Fournier, France, 50 mg/kg/day) by the oral
gavage. The dose was chosen after consideration of relevance to
human studies and assuming that oral dose of 45 mg/kg/day is
equivalent to 1 × MRHD (maximal recommended human dose,
(mg per m2 of body surface area)) for rats and 0.7 × MRHD for
mice, according to FDA Approved Drug Product database
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/). The
treatment started 7 days after tumor cell implantation. Following
10 days of daily drug administration the animals were euthanized
according to the standard ethically accepted procedures, and the
following body fluids/organs were collected: blood, urine, liver,
kidneys, spleen, heart, lungs, intact brain and intracranial tumor
tissue. These tissues were subjected to sample preparation for the
HPLC analysis (see below). All experiments were performed
according to the Guide for the Care and Use of Laboratory
Animals and local bioethical committee procedures at Louisiana
State University Health Science Center (IACUC approval #
2902).
Sample preparation
Blood plasma, cell culture media, cellular and tissue lysates,
and subcellular fractions were deproteinized by the addition of
150 µl of acetonitrile to 150 µl of sample, mixed well and
centrifuged (15,000 g, 5 min). Urine and other samples that did
not contain protein were centrifuged as above. In cell culture
experiments, subconfluent monolayer cultures were washed in
phosphate buffered saline (PBS) twice, then cells were scraped
and lysed in 2% sodium dodecyl sulphate (SDS) in PBS. The
lysates were sonicated on ice and centrifuged (15,000 g, 5 min).
Finally, 150 µl of the supernatant was mixed with the equal
volume of acetonitrile, filtered through 0.22 µm centrifuge filter
(Sigma) and analyzed by high performance liquid
chromatography (HPLC).
High performance liquid chromatography
All data were obtained from the Agilent Technologies
1100 apparatus equipped with a line degasser, binary pump
(high pressure mixer), autosampler, column thermostat and
Diode Array Detector (DAD). The YMCBase, 3 µm 4.6 × 150
mm analytical column was used and the solvent was 50 mM
acetic acid in 60% acetonitrile (in water). Flow rate was set to
1 ml/min, elution was isocratic, column temperature was
20°C, and 5 µl of filtered (0.22 µm) sample was injected.
DAD wavelength was set to 285 nm. Representative HPLC
chromatograms that show detection of FF and FA in biological
samples are shown in Fig. 2.
Western blot
The purity of the cytosolic and membrane fractions prepared
from the LN-229 cell lysates was checked by the detection of
protein markers characteristic for these fractions, namely N-
cadherin (rabbit monoclonal antibody from Cell Signaling
Technology, USA) for the membrane fraction and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, mouse
monoclonal antibody from Fitzgerald Industries, USA) for the
cytosolic fraction. Sample preparation and immunoblotting were
performed according to standard procedures described in our
previous publication (17).
Preparation of poly(glycolide-co-lactide) wafers containing
fenofibrate
The fabrication consisted of two-layered porous
biodegradable poly(glycolide-co-lactide) (PLGA) films, as
described previously by our laboratories (33, 34). In these
wafers, FF (Sigma Aldrich, USA) was incorporated into the
bottom layer and sealed with a second PLGA layer without drug,
as shown in Fig. 3a. The bottom layer was solvent cast and the
sealing layer was prepared by spin-coating. An 8 mm circular
piece of teflon, used as the substrate, was rinsed with 95%
ethanol to remove any surface contaminants. To prepare the
coating solution, 1.3% (w/v) of FF was first dissolved in
methylene chloride followed by addition of 12.5% (w/v) of the
PLGA (Resomer RG 506, 80 kDa) polymer to the solvent. The
solution was vortex-mixed to ensure homogeneity. The
appropriate volume (75 µL) of the solution containing PLGA
and the drug (~107 mg drug/g polymer) was solvent cast onto
the teflon at room temperature. Constant humidity was
maintained (~50–60% relative humidity) while the solvent was
slowly evaporated to produce a breath figure pattern on the film.
The breath figure technique is a facile method of producing
regular pores in the polymer film that enhance its drug delivery
properties (35-37). The drug-loaded film (~150 microns thick)
was dried for a day before fabricating the second layer. To coat
a second layer, 50 µL of 15% (w/v) PLGA solution in methylene
chloride (Resomer RG 504, 38-50 kDa) was spin coated at 1000
rpm for 25 s. This created a very thin film with an average
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Fig. 2. Detection of fenofibrate (FF) and fenofibric acid (FA) by high performance liquid chromatography [HPLC; AgilentTechnologies 1100 with on line degasser, binary pump, auto-sampler, 3 µm, 4.6 × 150 mm column YMCBase 3 µm, 4.6 × 150 mm
column (octyl silane C8 chemically bonded to totally porous silica particles), thermostat, and diode array detector (DAD)]. The sample
separation parameters: solvent a: 50 mM acetic acid in water, solvent b: acetonitrile, isocratic 60%; flow rate 1ml/min; temp 20°C;
injection fraction 5 µl; detection: DAD at 285 nm. (Panel a): HPLC chromatogram of FF and FA standards; (panel b): FF 50 µM
solution in human blood just after mixing (time 0); (panel c): the same solution as in B after 4 hours incubation at 37°C; (panel d):
HPLC analysis of urine from the patient who takes fenofibrate regularly (200 mg of micronized fenofibrate daily). FA and FF retention
times are 3.904 ± 0.004 min and 10.436 ± 0.084 min, respectively. Insets: UV-Vis absorption spectra for FF and FA showing absorption
maxima at 285 nm.
thickness of 20 microns that was intended to be a seal over the
first layer. Again, the second layer was cast in ~50–60% relative
humidity to create pores on the top layer (SEM photomicrograph
is shown in Fig. 3b). All fabricated samples were UV-sterilized
for an hour and stored until cell clonogenic assays.
Clonogenic assay
LN-229 cells were plated at the clonal density (1 × 103 cells
per 35 mm dish or well in a 6-well plate) in the DMEM-based
growth medium. The cells were exposed to the investigated
compounds (FF, Sigma Aldrich; gemfibrozil, Sigma Aldrich;
Wy-14,643, Cayman Chemicals, USA and metformin, Fluka;
and MK-886, Calbiochem, Merck Millipore, USA,) or to 1 mg
of FF incorporated in the PLGA wafer during the 12 days of
incubation. Control cells were treated with the vehicle (DMSO).
At the end of each experiment, the cells were fixed and stained
in the 0.25% crystal violet solution in methanol, air dried and the
colonies were counted. All the conditions were tested in
duplicate and each experiment was performed at least three
times.
Liposome preparation for electron paramagnetic resonance
analysis
L-α-phosphatidylcholine, dimyristoyl (DMPC) and
TEMPO-PC (T-PC) spin label were purchased from Avanti Polar
Lipids (USA), and other spin labels (5-SASL and 16-SASL)
were from Sigma (Germany). T-PC, 5-SASL and 16-SASL have
a nitroxide free radical moiety attached to the polar headgroup,
or to the 5th or 16th carbon atom in the alkyl chain, respectively.
Information can thus be obtained from three different regions of
the membrane: the water-membrane interface, the region close
to the polar headgroups or the membrane center. The membranes
used in this work were multilamellar liposomes of DMPC
containing 0, 2.5 or 5 mol% of FF and 1 mol% of lipid spin label,
prepared according to (38). All compounds were dissolved in
chloroform, which was then evaporated under stream of
nitrogen. The formed lipid film was then put under vacuum for
at least 12 hours. The dried lipids were suspended in 10 mM
borate buffer (pH 9.0) and vortexed. The multilamellar liposome
suspension was centrifuged at 14,000 rpm, for 15 min at 4°C,
and the pellet was used for EPR measurements.
Electron paramagnetic resonance measurements of membrane
fluidity and polarity
EPR measurements were performed using a Bruker EMX
spectrometer equipped with a temperature control unit.
Suspended multilamellar liposomes were placed in a gas
permeable capillary (i.d. 0.9 mm) made of Teflon and located
inside the EPR dewar insert in a resonant cavity of the
spectrometer. The sample was thoroughly deoxygenated with
nitrogen gas, which was also used for temperature control. In
case of DMPC phase transition measurements, the temperature
was changed in the range 25 to 20°C (cooling experiments) and
the spectra were recorded every 0.5°C (within the region of
phase transition (24–23°C), every 0.2°C). For polarity
measurements the samples were frozen to –150°C. The
parameter obtained from the EPR spectra of spin labels in frozen
membranes, Azz (z-component of the hyperfine interaction
tensor), depends only on the polarity of the surroundings (38).
RESULTS
Fenofibrate pharmacokinetics in cell culture
Our cell culture experiments have demonstrated that LN-229
human glioblastoma cells take up FF from culture medium, and
that intracellular esterases (most likely carboxylesterases or
arylesterases (39, 40)) metabolize FF to FA, which subsequently
accumulates in the medium. The results in Fig. 4 show the time
course of FF to FA exchange between cells and culture media. In
cells exposed to 50 µM FF, the drug accumulates quickly inside
the cells reaching the maximal concentration at 24 h, and then its
concentration gradually decreases (Fig. 4a). In contrast, FA
intracellular levels are much lower and constant during the
course of experiment (Fig. 4a). In the medium, FA levels
continuously increase, which together with the observed low
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Fig. 3. (Panel a): Schematic description of the preparation of
poly-lactic-co-glycolic acid (PLGA) wafers containing
fenofibrate. (Panel b): SEM image of highly porous PLGA film
cast using breath figure methodology. SEM images were
prepared as described in (33, 34).
intracellular FA levels, indicate that FA is continuously produced
inside the cells and is released to the medium (Fig. 4b).
However, it is also possible that FF may be processed to FA
outside the cell by secreted esterases. To test this alternative
interpretation, we collected conditioned medium from the LN-
229 cells cultured for 72 hours. This conditioned medium was
filtered (0.22 µm pore size filter), and 50 µM FF standard was
added for 24 hours at 37°C. Since we did not detect any traces
of FA after this procedure (data not shown), we concluded that
the filtered conditioned medium had no esterase activity and the
FA detected in Fig. 4b was most likely released from the cells
treated with FF.
Subcellular distribution of fenofibrate
Anticancer effects of PPARα agonists, FF in particular, have
been postulated by several laboratories, including ours (14-16,
41-44). In addition, some anticancer effects of FF are suspected
to be PPAR-independent, involving the antiangiogenic effects on
the tumor stroma (13, 41). It has been also reported that FF may
have cholesterol-like effects on biological membranes (28). Here
we demonstrate, for the first time, the detection of FF in the
membrane fraction isolated from human glioblastoma cells, LN-
229 (Fig. 5a). In these experiments, the cells were subjected to
subcellular fractionation following the treatment with 50 µM FF
for 24 hours. HPLC analysis of the membrane fraction showed a
single peak with a retention time that identified it as FF (data
shown in Fig. 6). The membrane fraction isolated from control,
DMSO-treated cells, was completely negative (data not shown).
To further verify that the obtained peak corresponded to FF, the
fraction was spiked with FF just before HPLC separation. This
procedure again generated a single peak that reflects
quantitatively the sum of detected membrane FF and the FF
spike (data not shown). When the cytosolic fraction was
analyzed, it generated two distinct peaks, one which
corresponded to FA and a second that corresponded to
unprocessed FF (Fig. 6). The data in Fig. 5a show the
quantitative analysis of FF and FA in cytosolic (cyto) and
membrane (mem) fractions isolated from 1 × 106 LN-229 cells
treated with 50 µM FF for 24 hours. In membrane fractions, we
detected 1.68 nmol of FF in a sample aliquot of 100 µl, which
corresponds to 5.04 nmol of FF in total membrane fraction
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Fig. 4. Fenofibrate (FF) and fenofibric acid (FA) concentrations
in whole cell lysates (a) and cell culture media (b) from the
monolayer culture of human glioblastoma cell line, LN-229
were treated with a single dose of fenofibrate (50 µM) FF and
FA were determined at the indicated time points using as
described in the materials and methods section. Data represent
average values from 2 experiments in triplicate (n=6) ± S.D.
(S.D. values for some points are too small to be visible).

Fig. 5. Fenofibrate (FF) and its metabolite, fenofibric acid (FA), in cell membrane and cytosolic fractions isolated from FF treated
human glioblastoma cell line, LN-229. (Panel a): quantitative analysis of FF and FA in membrane (mem) and cytosolic (cyto) fractions
isolated from LN-229 cells exposed to 50 µM fenofibrate (FF50) for 24 hours. Concentrations of FF and FA were calculated from the
corresponding calibration curves, and are expressed in nmols of FF and FA per 1 × 106 cells. Data represent average values from three
separate measurements with standard deviation. (Panel b): Western blot analysis demonstrating purity of cytosolic (Cyto) and
membrane (Mem) fractions in which N-cadherin and GAPDH were use as membrane and cytosolic markers, respectively.
isolated from 106 cells; the levels of FA were below our limit of
detection (~0.01 nmol for both FF and FA per 100 µl of sample).
Cytosolic fractions contained 7.20 nmol of FF and 1.71 nmol of
FA per 106 cells. The purity of analyzed subcellular fractions was
determined by Western blot analysis in which GAPDH served a
cytosolic marker, and N-cadherin as a membrane marker,
respectively (Fig. 5b). This novel finding indicates that only FF
partitions into biological membranes. This suggests that in
addition to the PPARα-mediated metabolic effects induced by
FA, FF itself could also contribute to the anticancer activity of
the drug via membrane-mediated processes. To test the
hypothesis that FF incorporated within the lipid bilayer alters
their properties, we performed the series of experiments with
spin labeling of model DMPC membranes.
Effects of fenofibrate on membrane properties
The mol% of fenofibrate relative to phospholipid in the
membranes of LN-229 cells was estimated from values of
phospholipid content in cell lysates reported for a LM mouse
fibroblast cell line (45). In these previous studies, the total
phospholipid in a cellular lysate ranged from 332–410 nmol/mg
protein, with an average of 364.5 nmol/mg protein. Based on this
average value for phospholipid content and back-calculating to the
amount of cellular protein present in the total membrane fraction
from 1 × 106 cells (0.3672 mg), we estimated the total
phospholipid in this fraction to be ~160 nmols and the mol% of
fenofibrate relative to phospholipid to be ~3.8% (5.04 nmol
FF/160.37 nmol phospholipid × 100). While we acknowledge that
such a calculation could vary 2-4-fold for different cultured cell
lines, this mol% calculation was used to guide our choice of 2.5
and 5 mol% fenofibrate in the EPR experiments described below.
Parameters characterizing the main phase transition of
lipids, such as the transition temperature (TM) and width (dT1/2)
reflect the membrane physical state and are very sensitive to
perturbations caused by some exogenous molecules. The main
phase transition of DMPC membranes was monitored by
observing the amplitude of the central line of the EPR spectra of
5 and 16-SASL (Ao). Fig. 7 shows the temperature dependence
of Ao for DMPC membranes containing 0, 2.5 and 5 mol% of FF.
These data demonstrate that FF shifts the TM to lower
temperatures and significantly broadens the phase transition in a
concentration-dependent manner. The values of phase transition
parameters obtained from these plots are presented in Tables 1
and 2. These tables also report additional data obtained from
EPR spectra of spin labels (the order parameter S for 5- and 16-
SASL and correlation times τ2B and τ2C for 16-SASL), which
reflect the degree of membrane fluidity. The effects of FF on
these parameters clearly depend on temperature. At 20°C (below
the TM of DMPC) a decrease in both S and correlation times is
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Fig. 6. HPLC-based detection of fenofibrate and its metabolite, fenofibric acid, in cell membrane (panel a) and cystolic fraction (panelb) isolated from fenofibrate treated human glioblastoma cell line, LN-229. Under these chromatographic conditions (see legend to Fig.
2), fenofibrate was eluted at 10.4 minutes and fenofibric acid at 3.9 min. Insets in (a) and (b) represent the unique UV-Vis absorbance
spectra of the obtained peaks corresponding to fenofibrate and fenofibric acid, respectively.
observed in the presence of FF, indicating a more fluid
membrane system, whereas at 25°C (above Tm of DMPC) a
slight increase of these parameters indicates that lipids are more
ordered in the presence of FF. Another important property of
membranes is the polarity at its different regions, and this can be
measured by EPR in frozen samples, since at –150°C a spectral
parameter 2AZ depends only on local polarity surrounding the
nitroxide moiety (38). Fig. 8 demonstrates hydrophobicity
profiles obtained for DMPC membranes in the absence and
presence of FF (2.5 or 5 mol%). FF clearly raises the
hydrophobicity barrier within the membrane (at positions C5
and C16), but does not affect the polarity in the membrane-water
interface. The effect is stronger in the region close to the polar
headgroups (C5) than in the membrane center (C16).
Fenofibrate distribution in tissues following oral
administration in mice
Considering possible anticancer application of FF, we
decided to evaluate tissue distribution of FF and FA in mice after
oral administration of 50 mg/kg/day of micronized FF. The
results of the HPLC analysis are reported in the Table 3.
Importantly, we did not detect FF in any of the analyzed tissues.
The FA was detected in the blood plasma, urine, liver, kidneys,
heart, spleen and lungs of the treated mice. In addition, we have
detected very small amounts of FA in the intact brain tissue in
two out of six mice treated with FF; however, LN-229 cells
growing intracranially in these animals were completely
negative. Our results are in close agreement with the previously
240
Fig. 7. Normalized amplitude of the
central peak of the EPR spectra of 5-
SASL (a) and 16-SASL (b) plotted as a
function of temperature (cooling
experiments) in DMPC bilayer.
Experiments were performed in the
absence and presence of FF (2.5 mol%
and 5 mol%). TM and dT1/2 were obtained
by fitting sigmoidal curves using Origin
software.
published data presenting the tissue distribution of 14C-
radiolabelled FF following oral administration in rats (46). The
authors confirmed the 14C presence in liver, kidney, guts, lung,
heart, spleen, testis, skin and epididymal fat, but almost none in
brain and eyes. Radioisotope detection is much more sensitive
than HPLC method, so this is strong evidence that neither FF nor
its metabolites cross blood brain barrier at the doses tested.
Similar results were obtained by Deplanque and coauthors (47),
who estimated that fenofibrate permeation rate in an in vitro
BBB model was very low, indicating that this drug can cross
BBB but extremely slowly. Taken together, these data indicated
that oral administration of FF may result in very limited uptake
in intracranial tumors and that uptake is dependent on the dose.
Poly-lactic-co-glycolic acid wafers for fenofibrate delivery to
the tumor site
Aggressive glial tumors are usually subjected to a surgical
excision, which is rarely complete, and frequently patients
experience tumor recurrence. Therefore, a direct delivery of the
drug into the cavity that is formed after tumor resection could
inhibit the glioblastoma cells that remain in the bed of the brain
tissue. The only controlled delivery system on the market,
Gliadel®, is a chemotherapeutic agent that cause side effects,
including a significantly higher risk of increased intracranial
hypertension (48). FF, in contrast, acts as neuroprotectant in
ischemic stroke and decreases cerebral infarct volume and brain
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Fig. 8. Hydrophobicity profiles (2Az)
across the DMPC membrane. Profiles
were obtained for the membranes without
additions and after addition of 2.5 mol%
or 5 mol% of FF. Upward changes (lower
values of the 2Az parameter) indicate
increase in hydrophobicity. Approximate
location of the nitroxide moieties of spin
labels are indicated by arrows. The
numbers with stars for n-SASLs indicate
that these SASLs are intercalated in the
right half of the bilayer, but the nitroxide
attached to C16 may pass through the
center of the bilayer and stay in the other
leaflet of the membrane. For more details
see (38).
DMPC  
5-SASL 
 
Tm [°C] 
 
dT1/2 [°C] 
S 
20 [°C] 25 [°C] 
control 23.199±0.042 0.352±0.036 0.729 0.622 
2.5 mol % FF 22.547±0.055 0.589±0.057 0.723 0.626 
5 mol % FF 20.711±0.519 1.446±0.260 0.703 0.630 
 
Table 1. Values of Tm, dT1/2 and order parameter S obtained from EPR spectra of 5-SASL in DMPC membranes in the absence and
presence of 2.5 or 5 mol% of FF.
DMPC 
16-SASL 
 
Tm [°C] 
 
dT1/2 [°C] 
S Ĳ2B[ns] Ĳ2C[ns] 
20°C 25°C 20°C 25°C 20°C 25°C
control 23.703±0.018 0.176±0.015 0.248 0.123 2.31 1.19 3.83 1.32 
2.5 mol % FF 23.198±0.338 0.348±0.287 0.255 0.119 2.17 1.18 3.60 1.29 
5 mol % FF 22.400±0.044 0.618±0.047 0.224 0.126 1.84 1.23 2.80 1.35 
 
Table 2. Values of Tm, dT1/2, order parameter S and correlation times obtained from EPR spectra of 16-SASL in DMPC membranes
in the absence and presence of 2.5 or 5 mol% of FF.
tissue injuries (47, 49); it is therefore much less likely to produce
adverse effects and might be even beneficial. We have
consequently developed a drug delivery system that would
slowly release FF upon contact with cerebrospinal fluid. We
employed a porous nanostructured poly-lactic-co-glycolic acid
(PLGA) polymer matrix as shown in Fig. 3b. PLGA is a
biodegradable, FDA approved polymer useful for both
hydrophobic and hydrophilic drug delivery applications (35).
The use of highly porous PLGA matrix incorporated FF
enabled slow release of the drug to the surrounding fluid with an
increasing rate that is a consequence of drug diffusion and wafer
erosion (33, 34). The results in Fig. 9 show that FF-loaded
PLGA matrix (PLGA/FF) submerged into the cell culture
medium began to release FF after 36 h, and the concentration of
the drug constantly increased, reaching almost 4 µM after 4 days
of the exposure. To determine whether the FF released from the
PLGA matrix was still active against glioblastoma cells, we
compared PLGA/FF with a single dose of 50 µM FF using the
LN-229 clonogenic assay. The results in Fig. 9b demonstrated
that the FF continuously released from the PLGA matrix
inhibited clonal growth of LN-229 cell even more potently than
a single dose of 50 µM FF. This could be attributed to a constant
release of the active drug from the matrix, which seems to have
an advantage over a single addition of FF. This is most likely
because FF is quickly converted to FA, which has significantly
lower anticancer activity in comparison to the unprocessed FF.
The results in Fig. 9c show cumulative concentrations of FF and
FA in culture media collected from the clonogenic assay, in
which the PLGA/FF wafer was continuously present for 12 days.
The data confirm the abundant presence of FF, which reached
concentration of almost 30 µM at day 12 of the clonogenic assay.
Conversely, we have detected only very low levels of FA in the
same medium, which could be explained by a very low number
of the tumor cells (capable of FF deesterification) due to FF-
induced inhibition of their clonogenic growth.
Since, FF-induced inhibition of glioblastoma clonogenic
growth is indeed quite remarkable, we decided to compare FF
with other known drugs that are postulated to have a similar
anticancer activity, including other agonists of PPARα,
gemfibrozil, Wy-14,643, and metformin, an anti-diabetic drug
that is believed to induce energetic stress in cancer cells (32).
The results in Fig. 9d show that FF is far more potent against
LN-229 cells when directly compared to gemfibrozil, Wy-
14,643 and metformin (all used at 50 µM, and with the addition
of a fresh aliquot for each drug every second day). The fact, that
those very specific PPARα agonists are not capable of
reproducing the FF effects suggests a receptor-independent
mechanism. Further evidence for an independent mechanism is
presented in Fig. 9e, which shows the results from the
clonogenic assay performed in the presence of a selective
PPARα inhibitor, MK-886 (50). MK-886 treatment did not
rescue the LN-229 cells from FF-induced growth retardation.
Unexpectedly, the cells treated with MK-886 and FF at the same
time experienced even stronger growth arrest and seemed to
have the proliferation blocked completely (Fig. 9e). These
results also suggest that PPARα-independent mechanism is a
strong contributing factor in this FF-mediated inhibition of LN-
229 cells, and that direct interaction between FF and cellular
membranes (Fig. 5a) could be involved.
DISCUSSION
As previously reported, FF exerts strong antiproliferative,
antimetastatic and proapoptotic activities towards various
tumors of neuroectodermal origin, including glioblastoma,
melanoma and medulloblastoma (13-17). This is a very
interesting finding for a drug that originally was used for
normalizing plasma lipid and lipoprotein profiles in patients
with hypercholesterolemia. The potent anticancer activity of FF
has gained much attention and led to its incorporation within
clinically applied drug regimens for patients with aggressive,
recurrent brain malignancies, childhood primitive
neuroectodermal tumors (PNETs) and leukemias. These
regimens include COMBAT (combined oral metronomic
biodifferentiating antiangiogenic treatment) and other
metronomic antiangiogenic therapies (29, 51, 52). Metronomic
chemotherapy is defined as chronic administration of
chemotherapeutic and cytostatic drugs at relatively low doses to
minimize toxicity and acute side effects (53). Importantly, this
treatment scheme omits the drug-free recovery periods that
usually lead to the tumor growth acceleration (30).
Antiangiogenic multidrug metronomic regimens combining
bevacizumab, thalidomide, celecoxib, etoposide,
cyclophosphamide and FF (30) or antiangiogenic differentiating
regimen that include temozolomide, etoposide, celecoxib,
vitamin D, FF and retinoic acid (29), are well tolerated and
produce encouraging effects in pediatric patients with aggressive
brain tumors. These benefits include increased 2-year survival,
good overall response to the treatment and only minor side
effects. Apart from being a treatment option for patients with
brain malignancies, FF has been shown to exert neuroprotective
effects in traumatic brain injuries and ischemic stroke (47). In
animal models of ischemic stroke that involve temporal middle
cerebral artery occlusion and subsequent reperfusion, mice
pretreated with FF had significantly decreased cerebral infarct
volume in the cortex and reduced oxidative stress in the brain
tissue (47). These effects have been attributed to the
antiinflammatory and antioxidative activity of PPARα, since FF
had no effect on ischemic/reperfusion injury in PPARα –/– mice.
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Tissue (mg)/body fluid (ml) 1FA (nmol/mg or /ml) 1FF (nmol/mg or /ml) 
Liver (n=6) 11.35 ± 3.9 0
Kidneys (n=6) 1.5 ± 0.8 0
Brain (n=5) 0.06 ± 0.1 0
Heart (n=4) 1.31 ± 1.4 0
Lungs (n=6) 0.36 ± 04 0
Spleen (n=4) 1.33 ± 1.1 0
Intracranial tumor (n=6) 0 0
Blood (n=6) 3.33 ± 1.6 0
Urine (n=5) 5.34 ± 2.4 0
 
Table 3. HPLC-based quantification of fenofibrate (FF) and fenofibric acid (FA) in different tissues and body fluids of mice fed with
micronized fenofibrate (50 mg/kg/day) over a period of four weeks. 1mean ±S.D.
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Fig. 9. Evaluation of PLGA wafer containing 1 mg of fenofibrate (FF). (Panel a): HPLC-based measurement of FF release to the
culture media, after submerging the PLGA wafer containing 1 mg of FF. The analysis was performed in the absence of cells. (Panel
b): Clonogenic growth of LN-229 cells in the presence of PLGA wafer containing 1 mg of FF (PLGA/FF); empty wafer (PLGA); and
FF in DMSO applied as a single 50 µM dose (FF 50 µM). (Panel c): FF and FA concentrations in LN-229 cells cultured in the presence
of PLGA/FF wafer for 12 days. (Panel d): Clonogenic assay in LN-229 cells treated with different PPARα agonists and metformin:
DMSO (vehicle), FF - fenofibrate 50 µM; Met - metformin 50 µM; Gem - gemfibrozil 50 µM; Wy - Wy14,643 50 µM. (Panel e):
Clonogenic assay in LN-229 treated with FF (25 µM), PPARα inhibitor MK-886 (10 µM) or both compounds together. Cells were
treated with the indicated compounds for 12 days; medium with the drugs was changed every second day.
Of note, in this study the FF/FA concentration in the brain was
not actually measured. To assess FF penetration to brain tissue,
the authors employed a blood-brain barrier (BBB) in vitro model
that consisted of bovine capillary endothelial cells and rat
astrocytes cocultured in the cell culture vessels with inserts (47).
The estimated BBB permeability coefficient for FA was very
low (0.68 × 10–3 cm/min) and similar to that of sucrose, so the
authors concluded that this molecule crosses BBB at a very slow
rate (47). Therefore, we might assume that the FA concentration
in the brain might teeter on the edge of detection limit of HPLC
method. Another interesting study that recognized a
neuroprotective potential of FF tried to address the problem of
poor access to the brain tissue through BBB by developing FF
and FA loaded PLGA microparticles for intracranial delivery
(54). The drug-containing microparticles were injected
intracranially to rats prior to the stroke induction. That procedure
allowed the injection of 10 µl of the suspension, which due to the
relatively low drug release rate (estimated not to exceed 0.004 %
daily, (54)) limited the drug accessibility area. It is remarkable
that in this study, FF, in contrast to FA, significantly reduced
cortical infarct volume, despite its much lower solubility (54). In
the light of our results, this might be attributed to better
solubility of FF in the neuronal plasma membranes. It cannot be
excluded that the neuroprotective activity of FF and the lack of
such for FA could be associated with the PPARα independent,
direct interactions of FF with biological membranes.
The study by Gamerdinger and colleagues (28) presented the
evidence that FF influenced the membrane fluidity in the manner
similar to cholesterol, and particularly increased the long-chain
fatty acid order that resulted in a thicker and more rigid
membrane. Indeed, the results reported herein with EPR and
model liposome membranes showed that FF affects membrane
fluidity and polarity in the manner similar to cholesterol, and at
even lower concentrations. The main phase transition of DMPC
is strongly affected by FF, which results in a membrane less
ordered below TM, and more ordered above TM. This is also
reflected by the changes of order parameter S and correlation
times (Table 2 and 3). The TM of DMPC is significantly shifted
to lower temperatures by FF, and at higher drug concentration,
no phase transition is observed at all, especially with 5-SASL.
Similar effects were observed in DMPC membranes after adding
nonsteroid anti-inflammatory drugs (NSAIDs) (55). Membranes
of such properties are typical for natural physiological
conditions where sudden fluidity changes (like from gel to liquid
phase at TM) do not take place. Also, the polarity decreases
observed in the presence of FF in the membrane center
(monitored by 16-SASL), and even to a higher degree, in the
region close to the lipid head groups (5-SASL), are important. It
was shown (38) that unsaturated lipid chains, as well as the
presence of cholesterol, decrease membrane polarity (creating a
hydrophobicity barrier). The level of unsaturated phospholipids
and cholesterol:phospholipid ratio also decline during
progressive carcinogenesis, thus rendering the membranes more
fluid (56). Addition of FF to such membranes could counteract
and compensate for these alterations and facilitate re-
establishing the hydrophobicity barrier, which is critical to
maintaining physiological homeostasis in healthy cells.
Stronger effects of FF on membrane properties were
observed close to the head group region of the membrane, which
suggests that FF is located predominantly in the region close to
the membrane surface. At the membrane-water interface,
however, the effect is not significant (i.e., only a slight increase
in head group mobility was observed by means of T-PC (data not
shown)), contrary to the strong effect of cholesterol in this region
(57). On the other hand, the observed decrease of TM in the
presence of FF may be caused by the disorganization of the
membrane in the region of the polar head groups (58).
The observed alterations in physical parameters of model
membranes suggest that FF is likely to change properties of
plasma membranes in the treated cells. Increased order above the
TM temperature, which is in the physiological range, may affect
activity of signal transduction molecules residing in the
membranes, such as phospholipase Cγ, protein kinase C (PKC)
or trimeric G proteins. All these proteins play crucial role in
triggering the signaling cascades from the membrane bound
growth factor receptors to the nucleus. Classical PKC
isoenzymes (α, βI, βII, γ) localized in the membranes are
subsequently activated by both diacylglycerol (DAG) and Ca2+
ions and amplify the signaling cascade through upregulation of
Ras/Raf-MEK and Erk pathway that controls cell survival,
proliferation and invasion (59). PKC activity depends on protein
- lipid interactions within membranes and fluid, less ordered
membranes with high propensity to non-lamellar hexagonal (HII)
phase formation strongly favor the PKC activation (60). PKC
activity is regulated by the membrane composition, which
determines the size of polar head group space and regional
bilayer curvature, showing a preference for a narrow range of
optimal content of some phospholipid species, such as
phosphatidylethanolamine (61). Phosphatidylethanolamine,
similarly to PKC activator DAG, is a cone shaped molecule with
a small polar head group. Membrane regions rich in this species
are less “packed” and possess larger head group spacing, as well
as a higher hydration level, which creates preferred
microenvironment for PKC (61-63). Slater and coworkers
studying in detail the influence of membrane microenvironment
on PKC activity concluded that “the narrow range over which
activation of the enzyme can be achieved indicates that the
enzyme may be highly sensitive to bilayer modifications that
lead to changes in head group spacing. Such modifications
include the presence of membrane perturbents such as drugs,
alcohol and anesthetics (61). Fenofibrate may be regarded as
such a substance. As our results depicted in Fig. 7 and 8 show,
FF increases hydrophobicity, particularly in the vicinity of
membrane surface (5-SASL), which is likely to affect activity of
lipid-submerged protein, such as PKC.
PKC isoenzymes are important oncogenes that boost up the
proliferation in various tumors, especially high-grade gliomas
(59, 64). Therefore, it is conceivable that FF-induced alterations
towards more ordered membranes downregulate PKC signaling
and triggers growth arrest in LN-229 cells. This statement can be
further supported by our previous observations that FF potently
inhibits phosphorylation of PKC down-stream effectors, such as
Erk1/2 in various cancer cells of neuroectodermal origin (16,
65). Some reports show that clofibrate and FF attenuate PKC
activation in endothelin-1 induced animal model of cardiac
hypertrophy, which alleviates the symptoms of this pathology
(66, 67). FF and FA have also been observed to inhibit PKC
enzymatic activity that drives platelet activation and aggregation
(68). Interestingly, in this case the effect was entirely PPARα
dependent and involved direct interaction of PPARα with PKC
(69). To make the situation even more complex, it was revealed
that PKC both stimulates PPARα expression and directly
phosphorylates PPARα protein on Ser179 and Ser230, which
enhances transactivation properties of this receptor (70).
The results of clonogenic assays performed on LN-229 cells
treated with potent PPARα agonists Wy-14,643 and gemfibrozil
and PPARα inhibitor MK-886 present the next rationale
suggesting that the strong anti-proliferative and anti-invasive
effects of FF against glioblastoma cells are largely PPARα
independent. Wy-14,643 or gemfibrozil are not able to reproduce
the growth suppressive effect of FF (Fig. 8d), and PPARα
inhibition by MK-886 could not reverse it (Fig. 8e). Conversely,
MK-886 administered together with FF showed synergistic
growth inhibitory effect (Fig. 8e). Logical explanation is that the
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FF accumulated in the cellular membranes is neither converted
into the PPARα ligand, FA, nor interacts with the nuclear
receptor.
In conclusion, it is likely that membrane-bound and PPARα-
independent action of FF is an important factor, which advocates
for the use of this drug in glioblastoma patients after tumor
resection. In this study we present the rationales for future
clinical trials with the FF- loaded PLGA matrices (wafers) to be
placed intracranially in the cavity that remains after glioma
resection, similarly to Gliadel® wafers. This approach,
combined with standard chemotherapy or metronomic treatment,
could limit both the danger of recurrence and reduce severe
toxicity and in consequence lead to substantial improvement in
the prognosis for the patients. PLGA is both biocompatible with
brain tissue and biodegradable, which means that the drug
release is driven by both diffusion through the polymer and
erosion (hydrolysis) of the carrier (54, 71). Both diffusion and
erosion require a liquid environment, which is present in the
tumor resection area. Such PLGA-based systems have already
been tested for carmustine, temozolomide and paclitaxel
delivery for glioma treatment (72, 73). One of PLGA’s
advantages is its relatively high hydrophobicity, which enables
efficient encapulation of nonpolar drugs such as FF. Slow release
of drug from the hydrophobic PLGA matrix might also favor
drug distribution into the lipid rich neuronal tissue.
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